Unknown

Dataset Information

0

Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators.


ABSTRACT: Cav1.2 and Cav1.3 are the main L-type Ca(2+) channel subtypes in the brain. Cav1.3 channels have recently been implicated in the pathogenesis of Parkinson's disease. Therefore, Cav1.3-selective blockers are developed as promising neuroprotective drugs. We studied the pharmacological properties of a pyrimidine-2,4,6-trione derivative (1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione, Cp8) recently reported as the first highly selective Cav1.3 blocker. Here we show, in contrast to this previous study, that Cp8 reproducibly increases inward Ca(2+) currents of Cav1.3 and Cav1.2 channels expressed in tsA-201 cells by slowing activation, inactivation and enhancement of tail currents. Similar effects are also observed for native Cav1.3 and Cav1.2 channels in mouse chromaffin cells, while non-L-type currents are unaffected. Evidence for a weak and non-selective inhibition of Cav1.3 and Cav1.2 currents is only observed in a minority of cells using Ba(2+) as charge carrier. Therefore, our data identify pyrimidine-2,4,6-triones as Ca(2+) channel activators.

SUBMITTER: Ortner NJ 

PROVIDER: S-EPMC4083433 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators.

Ortner Nadine J NJ   Bock Gabriella G   Vandael David H F DH   Mauersberger Robert R   Draheim Henning J HJ   Gust Ronald R   Carbone Emilio E   Tuluc Petronel P   Striessnig Jörg J  

Nature communications 20140619


Cav1.2 and Cav1.3 are the main L-type Ca(2+) channel subtypes in the brain. Cav1.3 channels have recently been implicated in the pathogenesis of Parkinson's disease. Therefore, Cav1.3-selective blockers are developed as promising neuroprotective drugs. We studied the pharmacological properties of a pyrimidine-2,4,6-trione derivative (1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione, Cp8) recently reported as the first highly selective Cav1.3 blocker. Here we show, in contras  ...[more]

Similar Datasets

| S-EPMC7699898 | biostudies-literature
| S-EPMC11352488 | biostudies-literature
2024-08-05 | GSE273169 | GEO
| S-EPMC4003244 | biostudies-literature
| S-EPMC3877713 | biostudies-literature
| S-EPMC2266581 | biostudies-literature
| S-EPMC3985108 | biostudies-literature
| S-EPMC10717889 | biostudies-literature
2022-06-09 | GSE186729 | GEO
| S-EPMC3626538 | biostudies-literature